熱門資訊> 正文

Protara Therapeutics GAAP每股收益为-0.37美元

2026-03-11 03:11

Protara Therapeutics, Inc.(TARA) 0

Protara Therapeutics press release (TARA): Q4 GAAP EPS of -$0.37.
As of December 31, 2025, unrestricted cash and cash equivalents and marketable debt securities totaled $197.9 million, including proceeds from the Company’s $86.3 million public offering in December 2025. The Company expects its cash and cash equivalents and marketable debt securities will be sufficient to fund its planned operations and milestones into 2028.

More on Protara Therapeutics

Protara Therapeutics, Inc. (TARA) Presents at 2026 ASCO Genitourinary Cancers Symposium - Slideshow
Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Invasive Bladder Cancer - Slideshow
Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Invasive Bladder Cancer Transcript
Protara gains as JP Morgan starts at overweight
Protara falls after mid-stage trial data for lead asset in bladder cancer

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。